Irish biotechnology company Priothera Ltd revealed on Thursday the addition of Elisabeth Kueenburg, M.D. as its chief medical officer.
As head of the company's medical department, Dr Kueenburg will lead the advancement of mocravimod into Phase 2b/3 clinical trials in 2022 for Acute Myeloid Leukemia (AML) patients undergoing hematopoietic stem cell transplantation as well as oversee the expansion of its pipeline.
Most recently, Dr Kueenburg served as clinical development lead at Celgene, where she supported the successful global launch of Revlimid.
Previously, Dr Kueenburg spent more than 15 years in clinical practice and academic research specializing in oncology and hematology.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA